Abstract
Despite the availability of several drugs, Mycobacterium tuberculosis is still a big concern for public health. Such situation exists because of continuous emergence of TB-resistant strains. Possible reasons of developing resistance include long therapy and combination therapy. Therefore new potential leads are needed to be identified, and at the same time, the number of drugs in the combination therapy should also be reduced that will make administration of drug doses easier. In the present scenario, developing drug having the ability to interact with multiple targets, simultaneously, is a promising approach to treat the complicated diseases. These multi-target drug therapies have advantage of improved safety profile and high drug efficacy with easier administration over the single-target drug therapies. Many of in silico methods have been applied to reach different polypharmacologically directed drug designing, mainly for multi-target drug designing. In this chapter, we have discussed about the available strategies for computational multi-target drug designing with their advantages and disadvantages. We have also discussed an easy, fast, and equally accurate method for multi-target drug designing against the Mycobacterium tuberculosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BCG:
-
Bacillus Calmette-Guerin
- CS:
-
Cycloserine
- DDI:
-
Drug-drug interactions
- DOTS:
-
Directly observed short-course chemotherapy
- EMB:
-
Ethambutol
- ETA:
-
Ethionamide
- FEL:
-
Free energy landscape
- IFN:
-
Interferon
- IGRA:
-
Interferon-gamma release assay
- INH:
-
Isoniazid
- MDR:
-
Multidrug resistant
- Mtb:
-
Mycobacterium tuberculosis
- ODE:
-
Ordinary differential equation
- PAS:
-
Para-amino salicylate
- PCA:
-
Principal component analysis
- PZA:
-
Pyrazinamide
- Rg:
-
Radius of gyration
- RIF:
-
Rifampin
- RMSD:
-
Root mean square deviation
- RMSF:
-
Root mean square fluctuation
- SASA:
-
Solvent-accessible surface area
- SMD:
-
Steered molecular dynamics
- TB:
-
Tuberculosis
- TDR:
-
Totally drug resistant
- TST:
-
Tuberculin skin test
- XDR:
-
Extensively drug resistant
References
World Health Organization (2016) Global TB Rep 2016
Cambau E, Drancourt M (2014) Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. Clin Microbiol Infect 20(3):196–201
Koike M, Takeya K (1961) Fine structures of intracytoplasmic organelles of mycobacteria. J Cell Biol 9(3):597–608
Imaeda T, Ogura M (1963) Formation of intracytoplasmic membrane system of mycobacteria related to cell division. J Bacteriol 85(1):150–163
Draper P (1971) The walls of Mycobacterium lepraemurium: chemistry and ultrastructure. Microbiology 69(3):313–324
Draper P, Kandler O, Darbre A (1987) Peptidoglycan and arabinogalactan of Mycobacterium leprae. Microbiology 133(5):1187–1194
Draper P (1998) The outer parts of the mycobacterial envelope as permeability barriers. Front Biosci 3:D1253–D1261
Moore DF, Curry JI (1998) Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by ligase chain reaction. J Clin Microbiol 36(4):1028–1031
Bloom BR (ed) (1994) Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, DC
Baltimore RS (2001) Tuberculosis: current concepts and treatment. Yale J Biol Med 74(6):413
Grange JM (1988) Mycobacteria and human disease. Edward Arnold (Publishers) Ltd, London
Rom WN, Garay S (1996) Tuberculosis Boston. Little, Brown and Company, New York, Toronto, London
Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845–855
Harries AD, Dye C (2006) Tuberculosis. Ann Trop Med Parasitol 100(5–6):415–431
Sutherland I, Švandová E, Radhakrishna S (1982) The development of clinical tuberculosis following infection with tubercle bacilli: 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63(4):255–268
Prasanthi K, Murty DS (2014) A brief review on ecology and evolution of mycobacteria. Mycobact Dis 4(6). https://doi.org/10.4172/2161-1068.1000172
Ernst JD (2012) The immunological life cycle of tuberculosis. Nat Rev Immunol 12(8):581–591
Zahrt TC (2003) Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection. Microbes Infect 5(2):159–167
Bodnar KA, Serbina NV, Flynn JL (2001) Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect Immun 69(2):800–809
Nguyen L (2016) Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol 90(7):1585
Davies PD (2003) The role of DOTS in tuberculosis treatment and control. Am J Respir Med 2(3):203–209
Zignol M, Gemert WV, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 90(2):111–119
Kahana LM (1996) The problem of drug resistance in tuberculosis. Chest 110(1):8–10
Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F (1994) Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271(9):698–702
Horwitz MA, Harth G, Dillon BJ, Masleša-Galić S (2000) Recombinant bacillus Calmette–Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97(25):13853–13858
Unissa AN, Selvakumar N, Narayanan S, Suganthi C, Hanna LE (2015) Investigation of Ser315 substitutions within katG gene in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from south India. Biomed Res Int 2015:257983
Centers for Disease Control and Prevention (2006) Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 55(1176):1
Revised National Tuberculosis Control Programme: National Strategic Plan for Tuberculosis Control 2012–2017
Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R (2008) Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci 29(2):62–71
Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF (2010) Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl Trop Dis 4(6):e721
Schneider G, Fechner U (2005) Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4(8):649–663
Rogawski MA (2000) Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents–toward an understanding of their favorable tolerability. Amino Acids 19(1):133–149
Nezami A, Kimura T, Hidaka K, Kiso A, Liu J, Kiso Y, Goldberg DE, Freire E (2003) High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 42(28):8459–8464
Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26(4):178–182
Pei J, Yin N, Ma X, Lai L (2014) Systems biology brings new dimensions for structure-based drug design. J Am Chem Soc 136(33):11556–11565
Schneider G (2014) Future de novo drug design. Mol Inform 33(6–7):397–402
Ramaswamy S (2007) Rational design of cancer-drug combinations. N Engl J Med 357(3):299–300
Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 5(3):202–210
Albert R, Jeong H, Barabási AL (2000) Error and attack tolerance of complex networks. Nature 406(6794):378–382
Ma W, Trusina A, El-Samad H, Lim WA, Tang C (2009) Defining network topologies that can achieve biochemical adaptation. Cell 138(4):760–773
Boran AD, Iyengar R (2010) Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 13(3):297
Radhakrishnan ML, Tidor B (2008) Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. J Chem Inf Model 48(5):1055–1073
Hu Y, Bajorath J (2013) Systematic identification of scaffolds representing compounds active against individual targets and single or multiple target families. J Chem Inf Model 53(2):312–326
Zhao S, Iyengar R (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52:505–521
Meng H, Liu Y, Lai L (2015) Diverse ways of perturbing the human arachidonic acid metabolic network to control inflammation. Acc Chem Res 48(8):2242–2250
Yang K, Bai H, Ouyang Q, Lai L, Tang C (2008) Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 4(1):228
Yang K, Ma W, Liang H, Ouyang Q, Tang C, Lai L (2007) Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol 3(3):e55
Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5(12):993–996
Halgren T (2007) New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 69(2):146–148
Laurie AT, Jackson RM (2005) Q-SiteFinder: an energy-based method for the prediction of protein–ligand binding sites. Bioinformatics 21(9):1908–1916
Hendlich M, Rippmann F, Barnickel G (1997) LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J Mol Graph Model 15(6):359–363
Yuan Y, Pei J, Lai L (2013) Binding site detection and druggability prediction of protein targets for structure-based drug design. Curr Pharm Des 19(12):2326–2333
Gao M, Skolnick J (2013) APoc: large-scale identification of similar protein pockets. Bioinformatics 29(5):597–604
Haupt VJ, Daminelli S, Schroeder M (2013) Drug promiscuity in PDB: protein binding site similarity is key. PLoS One 8(6):e65894
Günther S, Senger C, Michalsky E, Goede A, Preissner R (2006) Representation of target-bound drugs by computed conformers: implications for conformational libraries. BMC Bioinformatics 7(1):293
Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20(10–11):647–671
Moser D, Wisniewska JM, Hahn S, Achenbach J, Buscató EL, Klingler FM, Hofmann B, Steinhilber D, Proschak E (2012) Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. ACS Med Chem Lett 3(2):155–158
Irwin JJ, Shoichet BK (2016) Docking screens for novel ligands conferring new biology. J Med Chem 59(9):4103–4120
Liu J, He X, Zhang JZ (2013) Improving the scoring of protein–ligand binding affinity by including the effects of structural water and electronic polarization. J Chem Inf Model 53(6):1306–1314
Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, Murray CW (2011) Docking performance of fragments and druglike compounds. J Med Chem 54(15):5422–5431
Schomburg KT, Bietz S, Briem H, Henzler AM, Urbaczek S, Rarey M (2014) Facing the challenges of structure-based target prediction by inverse virtual screening. J Chem Inf Model 54(6):1676–1686
Lauro G, Romano A, Riccio R, Bifulco G (2011) Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. J Nat Prod 74(6):1401–1407
Wang X, Pan C, Gong J, Liu X, Li H (2016) Enhancing the enrichment of pharmacophore-based target prediction for the polypharmacological profiles of drugs. J Chem Inf Model 56(6):1175–1183
Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15(11):444–450
Xie L, Evangelidis T, Xie L, Bourne PE (2011) Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol 7(4):e1002037
Wu Y, He C, Gao Y, He S, Liu Y, Lai L (2012) Dynamic modeling of human 5-lipoxygenase–inhibitor interactions helps to discover novel inhibitors. J Med Chem 55(6):2597–2605
Shang E, Wu Y, Liu P, Liu Y, Zhu W, Deng X, He C, He S, Li C, Lai L (2014) Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1. Bioorg Med Chem Lett 24(12):2764–2767
Hartenfeller M, Zettl H, Walter M, Rupp M, Reisen F, Proschak E, Weggen S, Stark H, Schneider G (2012) DOGS: reaction-driven de novo design of bioactive compounds. PLoS Comput Biol 8(2):e1002380
Huang Q, Li LL, Yang SY (2010) PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility. J Mol Graph Model 28(8):775–787
DeWitte RS, Ishchenko AV, Shakhnovich EI (1997) SMoG: de novo design method based on simple, fast, and accurate free energy estimates. 2. Case studies in molecular design. J Am Chem Soc 119(20):4608–4617
DeWitte RS, Shakhnovich EI (1996) SMoG: de novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. J Am Chem Soc 118(47):11733–11744
Vinkers HM, de Jonge MR, Daeyaert FF, Heeres J, Koymans LM, van Lenthe JH, Lewi PJ, Timmerman H, Van Aken K, Janssen PA (2003) Synopsis: synthesize and optimize system in silico. J Med Chem 46(13):2765–2773
Fechner U, Schneider G (2006) Flux (1): a virtual synthesis scheme for fragment-based de novo design. J Chem Inf Model 46(2):699–707
Fechner U, Schneider G (2007) Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design. J Chem Inf Model 47(2):656–667
Böhm HJ (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6(1):61–78
Wang R, Gao Y, Lai L (2000) LigBuilder: a multi-purpose program for structure-based drug design. J Mol Model 6(7–8):498–516
Yuan Y, Pei J, Lai L (2011) LigBuilder 2: a practical de novo drug design approach. J Chem Inf Model 51(5):1083–1091
Shang E, Yuan Y, Chen X, Liu Y, Pei J, Lai L (2014) De novo design of multitarget ligands with an iterative fragment-growing strategy. J Chem Inf Model 54(4):1235–1241
Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR (2012) Automated design of ligands to polypharmacological profiles. Nature 492(7428):215–220
Reutlinger M, Rodrigues T, Schneider P, Schneider G (2014) Multi-objective molecular de novo design by adaptive fragment prioritization. Angew Chem Int Ed 53(16):4244–4248
Reutlinger M, Rodrigues T, Schneider P, Schneider G (2014) Combining on-chip synthesis of a focused combinatorial library with computational target prediction reveals imidazopyridine GPCR ligands. Angew Chem Int Ed 53(2):582–585
Rodrigues T, Hauser N, Reker D, Reutlinger M, Wunderlin T, Hamon J, Koch G, Schneider G (2015) Multidimensional De novo design reveals 5-HT2B receptor-selective ligands. Angew Chem 127(5):1571–1575
Giordano S, Petrelli A (2008) From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 15(5):422–432
Lu JJ, Pan W, Hu YJ, Wang YT (2012) Multi-target drugs: the trend of drug research and development. PLoS One 7(6):e40262
Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51(3):347–372
Kumar A, Sharma A (2018) Computational modeling of multi-target-directed inhibitors against Alzheimer’s disease. In: Computational modeling of drugs against Alzheimer’s disease. Humana Press, New York, NY, pp 533–571
Bajda M, Guzior N, Ignasik M, Malawska B (2011) Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem 18(32):4949–4975
DomÃnguez JL, Fernández-Nieto F, Castro M, Catto M, Paleo MR, Porto S, Sardina FJ, Brea JM, Carotti A, Villaverde MC, Sussman F (2014) Computer-aided structure-based design of multitarget leads for Alzheimer’s disease. J Chem Inf Model 55(1):135–148
Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A (2014) Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57(7):3126–3139
Speck-Planche A, V Kleandrova V, Luan F, Cordeiro ND (2012) In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis. Comb Chem High Throughput Screen 15(8):666–673
Rozwarski DA, Vilchèze C, Sugantino M, Bittman R, Sacchettini JC (1999) Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem 274(22):15582–15589
Lin W, Mandal S, Degen D, Liu Y, Ebright YW, Li S, Feng Y, Zhang Y, Mandal S, Jiang Y, Liu S (2017) Structural basis of Mycobacterium tuberculosis transcription and transcription inhibition. Mol Cell 66(2):169–179
Fan Y, Dai Y, Hou M, Wang H, Yao H, Guo C, Lin D, Liao X (2017) Structural basis for ribosome protein S1 interaction with RNA in trans-translation of Mycobacterium tuberculosis. Biochem Biophys Res Commun 487(2):268–273
Bolton EE, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: integrated platform of small molecules and biological activities. Annu Rep Comput Chem 4:217–241
Tiwari V, Patel V, Tiwari M (2018) In-silico screening and experimental validation reveal l-Adrenaline as anti-biofilm molecule against biofilm-associated protein (Bap) producing Acinetobacter baumannii. Int J Biol Macromol 107:1242–1252
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1–3):3–25
Wolf LK (2009) Digital briefs. Chem Eng News 87:31
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461
Goodsell DS, Morris GM, Olson AJ (1996) Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 9(1):1–5
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639–1662
Hess B, Kutzner C, Van Der Spoel D, Lindahl E (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4(3):435–447
Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26(16):1668–1688
Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781–1802
Wang J, Wang W, Kollman PA, Case DA (2001) Antechamber: an accessory software package for molecular mechanical calculations. J Am Chem Soc 222:U403
da Silva AW, Vranken WF (2012) ACPYPE-Antechamber python parser interface. BMC Res Notes 5(1):367
Mozolewska MA, Krupa P, Scheraga HA, Liwo A (2015) Molecular modeling of the binding modes of the iron-sulfur protein to the Jac1 co-chaperone from Saccharomyces cerevisiae by all-atom and coarse-grained approaches. Proteins 83(8):1414–1426
Turner PJ (2005) XMGRACE, Version 5.1. 19. Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology, Beaverton, OR
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33–38
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612
DeLano WL (2002) Pymol: an open-source molecular graphics tool. CCP4 Newsletter On Protein Crystallography 40:82–92
DeLano WL (2009) PyMOL molecular viewer: updates and refinements. In: Abstracts of papers of the American Chemical Society, 2009 Aug 16, vol 238. American Chemical Society, Washington, DC
Kumari R, Lynn A (2011) Application of MM/PBSA in the prediction of relative binding free energy: re-scoring of docking hit-list. J Nat Sci Biol Med 2(3):92
Kumari R, Kumar R, Open Source Drug Discovery Consortium, Lynn A (2014) g_mmpbsa—a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54(7):1951–1962
Amadei A, Linssen A, Berendsen HJ (1993) Essential dynamics of proteins. Proteins 17(4):412–425
Amadei A, Linssen AB, De Groot BL, Van Aalten DM, Berendsen HJ (1996) An efficient method for sampling the essential subspace of proteins. J Biomol Struct Dyn 13(4):615–625
Frauenfelder H, Sligar SG, Wolynes PG (1991) The energy landscapes and motions of proteins. Urbana 51(61801):61801
Isralewitz B, Gao M, Schulten K (2001) Steered molecular dynamics and mechanical functions of proteins. Curr Opin Struct Biol 11(2):224–230
Kumar S, Li MS (2010) Biomolecules under mechanical force. Phys Rep 486(1):1–74
Grubmüller H, Heymann B, Tavan P (1996) Ligand binding: molecular mechanics calculation of the streptavidin-biotin rupture force. Science 271(5251):997–999
Mai BK, Li MS (2011) Neuraminidase inhibitor R-125489—a promising drug for treating influenza virus: steered molecular dynamics approach. Biochem Biophys Res Commun 410(3):688–691
Suan Li M, Khanh Mai B (2012) Steered molecular dynamics—a promising tool for drug design. Curr Bioinforma 7(4):342–351
Van Vuong Q, Nguyen TT, Li MS (2015) A new method for navigating optimal direction for pulling ligand from binding pocket: application to ranking binding affinity by steered molecular dynamics. J Chem Inf Model 55(12):2731–2738
Chovancova E, Pavelka A, Benes P, Strnad O, Brezovsky J, Kozlikova B, Gora A, Sustr V, Klvana M, Medek P, Biedermannova L (2012) CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures. PLoS Comput Biol 8(10):e1002708
Mai BK, Viet MH, Li MS (2010) Top leads for swine influenza A/H1N1 virus revealed by steered molecular dynamics approach. J Chem Inf Model 50(12):2236–2247
Yang K, Liu X, Wang X, Jiang H (2009) A steered molecular dynamics method with adaptive direction adjustments. Biochem Biophys Res Commun 379(2):494–498
Gu J, Li H, Wang X (2015) A self-adaptive steered molecular dynamics method based on minimization of stretching force reveals the binding affinity of protein–ligand complexes. Molecules 20(10):19236–19251
Acknowledgments
G.S. and A.T. are thankful to ICMR, New Delhi, for their ICMR-SRF and ICMR-RA fellowship. Authors are also thankful to BTISnet program of DBT, New Delhi.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Srivastava, G., Tiwari, A., Sharma, A. (2018). Computational Methods for Multi-Target Drug Designing Against Mycobacterium tuberculosis. In: Roy, K. (eds) Multi-Target Drug Design Using Chem-Bioinformatic Approaches. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/7653_2018_19
Download citation
DOI: https://doi.org/10.1007/7653_2018_19
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8732-0
Online ISBN: 978-1-4939-8733-7
eBook Packages: Springer Protocols